MAPT and Alzheimer disease: This study was conducted before AD biomarkers like spinal fluid amyloid and tau levels, or amyloid and tau PET scans, were more commonly used, so the PPV of the clinical diagnosis is now likely higher than 83%; however, it remains imperfect.